Cargando…

Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis

Background: New direct-acting antiviral agents for hepatitis C genotype 1 infection, boceprevir and telaprevir, offer enhanced sustained virologic response (SVR) among both treatment-naïve and treatment-experienced patients. Aim: To determine the relative efficacy of the new direct-acting antiviral...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cooper, C., Lester, R., Thorlund, K., Druyts, E., El Khoury, A.C., Yaya, S., Mills, E.J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2013
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3550598/ https://www.ncbi.nlm.nih.gov/pubmed/23159839 http://dx.doi.org/10.1093/qjmed/hcs214

Ejemplares similares

Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for chronic hepatitis C infection
por: Druyts, Eric, et al.
Publicado: (2013)

Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection
por: Thorlund, Kristian, et al.
Publicado: (2012)

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
por: Cooper, Curtis L, et al.
Publicado: (2012)

SVR12 is higher than SVR24 in treatment-naïve hepatitis C genotype 1 patients treated with peginterferon plus ribavirin
por: Thorlund, Kristian, et al.
Publicado: (2014)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
por: Zanaga, L.P., et al.
Publicado: (2016)

Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis
por: Zoratti, Michael J., et al.
Publicado: (2020)

Economic evaluation of direct‐acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore
por: Wong, Yu‐Jun, et al.
Publicado: (2019)

Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting
por: Gayam, Vijay, et al.
Publicado: (2018)

Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China
por: Wang, Xiaozhong, et al.
Publicado: (2021)

Experience with direct-acting antivirals in genotype 1–5 infected chronic hepatitis C patients in Turkey
por: Sahin, Ahmet, et al.
Publicado: (2023)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters
por: Doyle, Mary-Anne, et al.
Publicado: (2019)

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment
por: Poordad, Fred, et al.
Publicado: (2017)

Hepatitis C direct‐acting antiviral outcomes in patients 75 years and older
por: Parmar, Parmvir, et al.
Publicado: (2020)

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure
por: Poordad, Fred, et al.
Publicado: (2018)

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement
por: Tag-Adeen, Mohammed, et al.
Publicado: (2017)

Direct‐acting antiviral therapy for chronic hepatitis C virus genotype 4 infection: Exploring new regimens
por: Toyoda, Hidenori
Publicado: (2019)

Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis
por: Luo, Aoran, et al.
Publicado: (2019)

Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam
por: Due, Ong The, et al.
Publicado: (2020)

Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection
por: Ohya, Kazuki, et al.
Publicado: (2019)

Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis
por: Thorlund, Kristian, et al.
Publicado: (2012)

Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study
por: Isfordink, Cas J, et al.
Publicado: (2021)

Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital
por: Hawsawi, Nahed Mohammed, et al.
Publicado: (2023)

Re-treatment of Hepatitis C Infection After Multiple Failures of Direct-Acting Antiviral Therapy
por: Fierer, Daniel S, et al.
Publicado: (2020)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Hepatitis C Virus-associated Membranoproliferative Glomerulonephritis Treated with Directly Acting Antiviral Therapy
por: Nayak, S., et al.
Publicado: (2018)

Impact of Interferon Lambda 4 Genotype on Interferon‐Stimulated Gene Expression During Direct‐Acting Antiviral Therapy for Hepatitis C
por: Ramamurthy, Narayan, et al.
Publicado: (2018)

Erratum to: Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study
por: Isfordink, Cas J, et al.
Publicado: (2021)

Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6
por: Due, Ong The, et al.
Publicado: (2019)

Direct-Acting Antiviral Use for Genotype 1b Hepatitis C Patients with Associated Hematological Disorders from Romania
por: Marincu, Iosif, et al.
Publicado: (2021)

Retrospective multicentre study on the effectiveness of first‐line direct‐acting antivirals against hepatitis C virus genotype‐1
por: Kaya, Michihiro, et al.
Publicado: (2022)

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD
por: Balk, Ethan M., et al.
Publicado: (2022)

Direct‐Acting Antiviral Treatment of Patients with Hepatitis C Resolves Serologic and Histopathologic Features of Autoimmune Hepatitis
por: Simoes, Camila C., et al.
Publicado: (2019)

Successful Kidney Transplantation in a Recipient Coinfected with Hepatitis C Genotype 2 and HIV from a Donor Infected with Hepatitis C Genotype 1 in the Direct-Acting Antiviral Era
por: Farmakiotis, Dimitrios, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q63jklrirrqsjltv1vvril2blr